Cue Biopharma (CUE) Interest Expenses (2017 - 2025)
Cue Biopharma (CUE) posted Interest Expenses of $16000.0 for Q4 2025, down 97.27% sequentially from $586000.0 in Q3 2025, and up 103.58% YoY from $7859.3 in Q4 2024.
Cue Biopharma (CUE) Interest Expenses (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Interest Expenses for 9 years, with the latest figure at $16000.0 in Q4 2025.
- Quarterly Interest Expenses rose 103.58% year-over-year to $16000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$390000.0 (down 413.16% YoY) and the FY2025 annual result came in at $988000.0, down 79.3% from the prior year.
- Interest Expenses retreated to $16000.0 in Q4 2025 per CUE's latest filing, from $586000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $6.3 million in Q1 2021 and troughed at -$668000.0 in Q4 2023.
- A 5-year average of $1.7 million and a median of $458000.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses tumbled 409.26% in 2023, then jumped 3622.54% in 2024.
- Over 5 years, Interest Expenses stood at $1.3 million in 2021, then sank by 83.19% to $216000.0 in 2022, then sank by 409.26% to -$668000.0 in 2023, then surged by 33.08% to -$447000.0 in 2024, then jumped by 103.58% to $16000.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $16000.0, $586000.0, and $5.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Jun 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 5.93 Mn |
| Mar 31, 2025 | 3.91 Mn |
| Mar 31, 2025 | 3.91 Mn |
| Dec 31, 2024 | -447,000.00 |
| Dec 31, 2024 | -447,000.00 |
| Sep 30, 2024 | 818,000.00 |
| Sep 30, 2024 | 818,000.00 |
| Jun 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 6.15 Mn |
| Mar 31, 2024 | 6.15 Mn |
| Dec 31, 2023 | -668,000.00 |
| Dec 31, 2023 | -668,000.00 |
| Sep 30, 2023 | 709,000.00 |
| Sep 30, 2023 | 709,000.00 |